Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.
- 1 November 2012
- journal article
- review article
- Vol. 12 (9), 1129-59
Abstract
Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.Keywords
This publication has 100 references indexed in Scilit:
- Sampling variability of liver fibrosis in chronic hepatitis CHepatology, 2003
- Grape extracts suppress the formation of preneoplastic foci and activity of fatty acid synthase in rat liverExperimental & Molecular Medicine, 2003
- Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosisThe Esophagus, 2003
- Inflammation and cancerNature, 2002
- Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouseHepatology, 2002
- Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1AThe FASEB Journal, 2002
- Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesisOncogene, 2000
- Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGFβ-1 in liverEuropean Journal of Cancer, 1999
- Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomyZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Prevention by acetylsailcylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, L-amino acid-defined diet in ratsCarcinogenesis: Integrative Cancer Research, 1994